How do I structure a PhD proposal for an international fellowship application?

Check whether your institution has a Springer/Elsevier waiver agreement.many NITs and IITs do.

This question comes up a lot. The answer really depends on your specific field and what your committee values.

As a senior faculty member (25 years in the system), I want to offer a different perspective. Yes, the pressures are real. But I have also seen the other side: students who produce excellent work, publish honestly, and build reputations over time. The system is imperfect but not entirely broken.

What has actually helped my students: choosing venues carefully (a few strong papers rather than many weak ones), developing genuine collaborations rather than transactional coauthorships.

This is exactly what I needed to hear. One clarifying question: you mentioned FedProx handles non-IID data better.does that mean I should switch to FedProx by default, or only if I observe poor convergence with FedAvg first?

Respectfully, I think this framing misses the systemic dimension. Individual researchers cannot solve a collective action problem. If you submit to open-access journals and your colleague submits to Nature, your colleague gets the promotion. Until evaluation criteria change at the institutional level.which requires policy intervention.individual choices have minimal impact.

I have a slightly different take from my experience in industry research. The reproducibility crisis is real but unevenly distributed. Fields with strong engineering culture (computational biology, ML with benchmarks) have actually improved significantly in the last 5 years. The bigger problem is in fields where data sharing is structurally difficult.clinical medicine, behavioral economics.

The ML community's move toward open code and reproducibility checklists has been genuinely effective.

Open access is the right direction but the APCs are prohibitively expensive for many Indian researchers without institutional funding.

Open access is the right direction but the APCs are prohibitively expensive for many Indian researchers without institutional funding.

For longitudinal data with missing values, mixed-effects models handle this more gracefully than imputation in most cases.

The ethics review situation in Indian universities is actually more complex than most people realize.

There is no uniform national framework equivalent to the US Common Rule. Each institution has its own Institutional Ethics Committee (IEC) or Institutional Review Board (IRB).

For anonymous survey research with no identifiable data and no vulnerable populations: most Indian IECs would classify this as exempt, but 'exempt' still needs a formal determination from the IEC.it is not self-certifying.

My practical advice: go to your institution's research ethics office now, describe what you did, and request an exempt determination in writing. Better to have documentation than to discover the issue during thesis review.

Flower (flwr) is the most actively maintained and research-friendly federated learning framework right now. My group has been using it for 18 months on a healthcare project with 4 hospital sites.

Strengths:

• Clean simulation API that lets you test on a single machine before deploying
• Good support for custom aggregation strategies (FedProx, FedNova)
• Active Discord community with quick responses from the maintainers

For non-IID data specifically, look at the FedProx strategy.it handles heterogeneous data distributions much better than FedAvg.

Check whether your institution has a Springer/Elsevier waiver agreement.many NITs and IITs do.

Could you clarify what you mean by results-blind review? I have heard of it but never understood how it works in practice. Wouldn't reviewers need to see results to evaluate whether the methodology is sound?

As a senior faculty member (25 years in the system), I want to offer a different perspective. Yes, the pressures are real. But I have also seen the other side: students who produce excellent work, publish honestly, and build reputations over time. The system is imperfect but not entirely broken.

What has actually helped my students: choosing venues carefully (a few strong papers rather than many weak ones), developing genuine collaborations rather than transactional coauthorships.

I have a slightly different take from my experience in industry research. The reproducibility crisis is real but unevenly distributed. Fields with strong engineering culture (computational biology, ML with benchmarks) have actually improved significantly in the last 5 years. The bigger problem is in fields where data sharing is structurally difficult.clinical medicine, behavioral economics.

The ML community's move toward open code and reproducibility checklists has been genuinely effective.

The short answer: it depends heavily on the journal and field, but here is a general framework.

If your null result is well-powered and the hypothesis was reasonable: Absolutely publish it. Null results in well-designed studies are as valuable as positive results. Journals like PLOS ONE explicitly welcome them.

If your study is underpowered: Be transparent about it. Report effect sizes and confidence intervals, not just p-values. A small, underpowered study with honest reporting is still a contribution.

What kills papers is when limitations are obvious but the authors have not addressed them.

Flower (flwr) is the most actively maintained and research-friendly federated learning framework right now. My group has been using it for 18 months on a healthcare project with 4 hospital sites.

Strengths:

• Clean simulation API that lets you test on a single machine before deploying
• Good support for custom aggregation strategies (FedProx, FedNova)
• Active Discord community with quick responses from the maintainers

For non-IID data specifically, look at the FedProx strategy.it handles heterogeneous data distributions much better than FedAvg.

I'd push back slightly on the idea that industry collaboration is universally beneficial for academic research. The incentive misalignment is real.

Industry partners want deliverables on a schedule. Academic research is often exploratory and unpredictable. When the two clash, it is usually the researcher who has to compromise.either by rushing results, constraining publication, or steering away from results that are inconvenient for the sponsor.

This doesn't mean industry collaboration is bad. But the terms matter enormously. IP rights, publication rights, and the ability to pursue negative results should be negotiated upfront and protected in writing.

The ethics review situation in Indian universities is actually more complex than most people realize.

There is no uniform national framework equivalent to the US Common Rule. Each institution has its own Institutional Ethics Committee (IEC) or Institutional Review Board (IRB).

For anonymous survey research with no identifiable data and no vulnerable populations: most Indian IECs would classify this as exempt, but 'exempt' still needs a formal determination from the IEC.it is not self-certifying.

My practical advice: go to your institution's research ethics office now, describe what you did, and request an exempt determination in writing. Better to have documentation than to discover the issue during thesis review.

Seconding the recommendation for Zotero. Game changer for managing references across multiple projects.

Open access is the right direction but the APCs are prohibitively expensive for many Indian researchers without institutional funding.

Could you clarify what you mean by results-blind review? I have heard of it but never understood how it works in practice. Wouldn't reviewers need to see results to evaluate whether the methodology is sound?

Highly recommend checking out the PMRF portal for the actual numbers.they update the stipend structure annually.

I found that writing a paper abstract first (before the paper) and then reverse-engineering the paper from the abstract helped with clarity enormously.